1
|
Van den Abbeele AD, Sakellis CG, George S. PET imaging of Gastrointestinal Stromal Tumors (GIST). Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00110-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
2
|
Chacón M, Eleta M, Espindola AR, Roca E, Méndez G, Rojo S, Pupareli C. Assessment of early response to imatinib 800 mg after 400 mg progression by 18F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors. Future Oncol 2015; 11:953-64. [DOI: 10.2217/fon.14.292] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
ABSTRACT Introduction: Imatinib is the standard first-line therapy for advanced gastrointestinal stromal tumor. 18F-fluorodeoxyglucose PET computed tomography (FDG PET/CT) shows a faster response than computed tomography in nonpretreated patients. Patients & methods: After disease progression on imatinib 400 mg, 16 patients were exposed to 800 mg. Tumor response was evaluated by FDG PET/CT on days 7 and 37. Primary objective was to correlate early metabolic response (EMR) with progression-free survival (PFS). Results: EMR by FDG PET/CT scan was not predictive of PFS. Median PFS in these patients was 3 months. Overall survival was influenced by gastric primary site (p = 0.05). Conclusion: The assessment of EMR by FDG PET/CT in patients with advanced gastrointestinal stromal tumor exposed to imatinib 800 mg was not predictive of PFS or overall survival.
Collapse
Affiliation(s)
- Matías Chacón
- Grupo Argentino de Tumores Estromales Digestivos (GATE-D), Buenos Aires 1426, Argentina
| | - Martín Eleta
- Grupo Argentino de Tumores Estromales Digestivos (GATE-D), Buenos Aires 1426, Argentina
| | | | - Enrique Roca
- Grupo Argentino de Tumores Estromales Digestivos (GATE-D), Buenos Aires 1426, Argentina
| | - Guillermo Méndez
- Grupo Argentino de Tumores Estromales Digestivos (GATE-D), Buenos Aires 1426, Argentina
| | - Sandra Rojo
- Grupo Argentino de Tumores Estromales Digestivos (GATE-D), Buenos Aires 1426, Argentina
| | - Carmen Pupareli
- Grupo Argentino de Tumores Estromales Digestivos (GATE-D), Buenos Aires 1426, Argentina
| |
Collapse
|
3
|
|